Patients undergoing systemic anti-cancer therapy who require surgical intervention: what surgeons need to know
Name:
37568597.pdf
Size:
1.114Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Robinson, M. D.McNamara, Mairead G
Clouston, Hamish W
Sutton, Paul A
Hubner, Richard A
Valle, Juan W
Affiliation
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester M13 9NT, UKIssue Date
2023
Metadata
Show full item recordAbstract
As part of routine cancer care, patients may undergo elective surgery with the aim of long-term cure. Some of these patients will receive systemic anti-cancer therapy (SACT) in the neoadjuvant and adjuvant settings. The majority of patients, usually with locally advanced or metastatic disease, will receive SACT with palliative intent. These treatment options are expanding beyond traditional chemotherapy to include targeted therapies, immunotherapy, hormone therapy, radionuclide therapy and gene therapy. During treatment, some patients will require surgical intervention on an urgent or emergency basis. This narrative review examined the evidence base for SACT-associated surgical risk and the precautions that a surgical team should consider in patients undergoing SACT.Citation
Robinson MD, McNamara MG, Clouston HW, Sutton PA, Hubner RA, Valle JW. Patients Undergoing Systemic Anti-Cancer Therapy Who Require Surgical Intervention: What Surgeons Need to Know. Cancers (Basel). 2023 Jul 26;15(15). PubMed PMID: 37568597. Pubmed Central PMCID: PMC10417541. Epub 2023/08/12. eng.Journal
CancersDOI
10.3390/cancers15153781PubMed ID
37568597Additional Links
https://dx.doi.org/10.3390/cancers15153781Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.3390/cancers15153781